...MedImmune Inc., a subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) is developing MEDI-528, and MacroChem Corp....

...of development of resistance during treatment with pexiganan. Data were published in Clinical Infectious Diseases. MacroChem...
...an exclusive, worldwide license to pexiganan from Genaera. In July, Access announced a merger with MacroChem...
...BioCentury, July 14). Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Genaera Corp. (NASDAQ:GENR), Plymouth Meeting, Pa. MacroChem Corp....

...a 46% response rate vs. 47% for ofloxacin. Data were published in Clinical Infectious Diseases. MacroChem...
...an exclusive, worldwide license to pexiganan from Genaera. In July, Access announced a merger with MacroChem...
...BioCentury, July 14). Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Genaera Corp. (NASDAQ:GENR), Plymouth Meeting, Pa. MacroChem Corp....

...area. Also, 8 patients met the study's secondary endpoint of negative mycology at 48 weeks. MacroChem Corp....

...Access will acquire MacroChem for 2.5 million shares valued at $8 million based on Access’ close...
...9, the day before the deal was announced. The deal gives Access full rights to MacroChem’s...
...leukemia and advanced prostate cancer and which was already partnered with Access. Access also gets MacroChem’s...

...a topical anti-infective that has completed two Phase III trials to treat diabetic foot infection. MacroChem...
...2007, MacroChem had $3.2 million in cash and a full-year operating loss of $5.9 million. MacroChem Corp....
...Drug delivery MacroChem acquired Virium for 22.9 million shares valued at $6.9 million based on MacroChem's...